Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Featured trial
Switch Maintenance in Pancreatic

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body.This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells.The names of the study drugs involved …

  • 0 views
  • 24 Nov, 2025
  • 1 location
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX). Main objective of the study is median overall survival.

fluorouracil
flot regimen
gastric adenocarcinoma
flot
immunodeficiency
  • 0 views
  • 19 Feb, 2024
  • 1 location
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin (FOLFOX6), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan (mFOLFIRINOX). Main objective of the study is progression free survival.

fluorouracil
carcinoma
gastric adenocarcinoma
immunodeficiency
adenocarcinoma of the gastroesophageal junction
  • 0 views
  • 19 Feb, 2024
  • 1 location
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. The study …

measurable disease
solid tumor
solid tumour
colorectal cancer
serum pregnancy test
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

measurable disease
invasive breast cancer
estrogen
stage iv breast cancer
whole brain radiotherapy
  • 8 views
  • 19 Feb, 2024
  • 1 location